Britannia Pharmaceuticals Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 1981-01-01
- Employees
- 51
- Market Cap
- -
Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients with Advanced Parkinson's Disease
Active, not recruiting
- Conditions
- Advanced Parkinson Disease
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Britannia Pharmaceuticals Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05043103
- Locations
- 🇦🇹
Universitätsklinik für Neurologie, Medizinische Universität Graz, Graz, Austria
🇦🇹Abteilung für Neurologische Rehabilitation, Gailtal-Klinik, Hermagor, Austria
🇦🇹Universitätsklinik für Neurologie, Medizinische Universität Innsbruck, Innsbruck, Austria
Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
Phase 3
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Britannia Pharmaceuticals Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT02006121
- Locations
- 🇦🇹
Medizinische Universität Graz / Univ. Klinik für Neurologie, Graz, Austria
🇳🇱Universitair Medisch Centrum, Groningen, Netherlands
🇦🇹Donauspital / SMZ-Ost, Abteilung für Neurologie, Sekretariat (Stock 1, Ebene 4), Vienna, Austria
Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
Phase 2
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Britannia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT00346827
© Copyright 2025. All Rights Reserved by MedPath